Expert interpretation: Pfizer vaccine is 94% effective in the real world?

Expert interpretation: Pfizer vaccine is 94% effective in the real world?  According to Reuters, Lianhe Zaobao and other media citing an Israeli study, the effective rate of the COVID-19 vaccine jointly developed by Pfizer and BioNTech in the real world is expected to reach 94%, which is consistent with the data in the Phase III clinical trial. In addition, the effective rate of single injection of the vaccine can reach 57% after 14 days. This is Pfizer Vaccine’s first real-world research data in the world.

Up to now, most of the data on the effectiveness of the COVID-19 vaccine have been conducted under controllable clinical trials, and its actual effectiveness in the real world is still uncertain. According to Reuters, a study in Israel, which has the fastest vaccination rate in the world, shows that among all age groups in practice, the effective rate of two doses of Pfizer vaccine on symptomatic cases is about 94%, and the effective rate for severe illness is also Similar to this.

This research data has been published in the “New England Journal of Medicine” on the 24th and has been peer reviewed. The research is in charge of the Clarit Institute, which belongs to Israel’s largest health system, and the research object is 1.2 million people in reality. The relevant research results are considered to be very similar to the results of Pfizer’s Phase III clinical trial last year.

According to preliminary data collected by the Department of Public Health England from medical staff, two doses of Pfizer vaccine can reduce the risk of COVID-19 infection by 85%. “Our data show that vaccination not only reduces symptomatic infections, but also reduces the number of asymptomatic infections,” said Hopkins, Director of Strategic Response at the Department of Public Health England.

Doctor Zhuang Shilihe, who has been paying attention to the vaccine industry for a long time, said in an interview with a reporter from the Global Times on the 25th that the research on efficiency in the real world is more difficult than the phase three trial, but it is also more meaningful. Because the three phase trials are clearly grouped and more controllable, and there are various factors in the real world. “Pfizer’s data in practice is highly consistent with the results of its Phase III trial, which is very exciting and confirms the effectiveness of this vaccine.”

What is worth mentioning is the data on the effective rate of only one dose of vaccine in two studies in Israel and the United Kingdom: in the Israeli study, the effective rate of a single injection in preventing symptomatic infections was 57%; and in the study in the United Kingdom , One dose of vaccine can reduce the risk of COVID-19 infection by more than 70%.

Zhuang Shilihe believes that there is a big difference between single-dose and two-dose vaccines in terms of epidemic prevention. The single-dose vaccination procedure is simple and can vaccinate more people in the same time period, which is beneficial to protect as much as possible in the shortest time. Many crowds. If a single dose of a vaccine has a high efficiency, when the vaccine supply is relatively short at the initial stage of large-scale vaccination, one dose can be considered first, and the interval between vaccination can be extended as much as possible, so that more people can be immunized. However, this path must be supported by data.

However, another expert in the field of immune health told the Global Times reporter that the relevant data of Israel and the United Kingdom need to be further studied and confirmed later, because as of now, the number of new infections in a single day in Israel has not seen a significant drop. . He believes that the effectiveness of vaccines in anti-epidemic practice is more complicated, and statistics are more difficult, and it takes longer to test the effectiveness of a vaccine.

(source:internet, reference only)

Disclaimer of medicaltrend.org